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Abstract—Cancer fighting treatments are expanding, and a
promising type, targeted molecular therapies have a new ap-
proach. The aim of these therapies is not to eliminate the
whole tumor, but to control the tumor into a given state and
keep it there. Explicit knowledge of tumor growth dynamics
and the effects of targeted molecular therapies is crucial in
tumor treatment development. We show the results of mouse
experiments where tumor growth was investigated in case of
C38 colon adenocarcinoma and B16 melanoma. Several curves
were fitted and tumor growth dynamics was examined. Three
attributes of tumor were measured: tumor volume, tumor mass
and vascularization; and tumor growth dynamics was examined.
Tumor volume was measured with digital caliper, vascularization
was investigated with CD31 antibody immunohistochemistry
staining on frozen sections. The relationship between these tumor
attributes were examined with linear regression analysis. The
dynamics of tumor growth was identified as a second order linear
system.
I. INTRODUCTION
Conventional cancer therapies are surgical oncology,
chemotherapy and radiotherapy. With surgical oncology [1]
the tumor cells can be totally removed (zero-order kinetics); in
contrast using chemotherapy [2] or radiation therapy [3], only
a fraction of tumor cells are killed (first-order kinetics). The
problem with surgical intervention is the fact, that tumor can
recurrent in many cases [4]. Chemotherapy and radiotherapy
act in general ways (by killing rapidly dividing cells), so
these treatments have a lot of side effects and tumor cells
can become resistant to chemotherapy drugs, which makes the
usage of new drugs necessary. That is the reason, why there
is a new, dynamically developing therapeutic group called
targeted molecular therapies (TMTs). These treatments fight
specifically against different cancer mechanisms, hereby these
therapies can be more effective and have limited side effects.
The main differences between conventional cancer therapies
and targeted molecular therapies are not only the acting ways,
but also the goals. Using conventional treatments, there is no
need to know how cancer cells are developing and which
mechanisms are used to circumvent the immune system. The
goal of conventional cancer therapies is to eliminate the tumor
mass, but after a certain time the tumor can recrudesce and
give metastasis. Targeted therapy represents a new approach:
it acts in specific molecular ways, and the goal is to prevent
tumor cells from growth and develop; hence preventing toxi-
city. This is more important than eliminating the tumor mass
– for the patients there is a better chance of survival if they
have inactive tumor mass, than if they don’t have tumor for a
while, but there is the risk of recurrence. In order to develop
targeted therapies, it is required to analyze tumor growth and
explore causal factors, but with this knowledge these therapies
have led to truly tailored therapy [5] with reduced side effects
[6].
The process of analyzing tumor growth belongs to the
science of molecular oncology. The aim of targeted molecular
therapies is not to eliminate the whole tumor, but to control the
tumor into a given state and keep it there. This task belongs to
the science of control engineering that can provide effective
assistance to model-based therapies, which examine tumor
growth as a dynamic system [7], [8]. We have investigated
existing tumor growth models from the literature and designed
different control algorithms [9], [10], [11], [12]. In this paper
we summarize the results of our animal experiments and
present our identified tumor growth model for C38 colon
adenocarcinoma and B16 melanoma.
The paper is organized as follows. In Section II, the
oncopathological background (properties of the investigated
tumor types) of the research is described. In Section III, the
methods used in the present study are described. Experimental
results are shown is Section IV, followed by the identification
of tumor growth dynamics and correlation analysis of tumor
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attributes. The paper ends in Section V with the conclusion
and further research possibilities.
II. ONCOPATHOLOGICAL BACKGROUND OF THE
EXPERIMENT
C38 colon adenocarcinoma is a mouse tumor, which is
originated from columnar epithelium of colon’s mucosa. Ade-
nocarcinoma means "a malignant epithelial tumor with glan-
dular differentiation or mucin production" [13]. Properties of
C38 adenocarcinoma are: (a) because this is a mouse tumor,
it grows fast in mice (since 2-3 weeks it reaches a lethal
size); (b) also because its specificity, there is no need to
use immunosuppressed mice; (c) a piece of tumor can be
implanted subcutaneously into the mice; (d) typically does
not metastasize; (e) tumor cells inflict strong hypoxial reaction
[14]. C38 tumor also has a large relative vascular area [15],
which is beneficial if we would like to examine the effect of
angiogenic inhibition later.
B16 melanoma ([16], [17]) is a mouse tumor, it is a
primer melanoma. "Melanomas are malignant tumors derived
from melanocytes" [13]. The pattern can be variable, usually
the cytoplasm contains melanin granules. Properties of B16
melanoma are: (a) because this is a mouse tumor, it grows
very fast in mice (since 2 weeks it reaches a lethal size); (b)
also because its specificity, there is no need to use immuno-
suppressed mice; (c) it can be injected intramuscularly; (d)
typically does not metastasize. B16 mice melanoma can be
used as a model for human melanoma [18].
C38 colon adenocarcinoma and B16 melanoma are widely
and for a long while used mouse experimental tumors from
the standard NCI (National Cancer Institute) screening [19],
[20].
III. DESCRIPTION OF THE EXPERIMENT
In this section we give a brief description of the methods
used during the mouse experiments.
A. Tumor implantation
In case of C38 colon adenocarcinoma a piece of tumor
was transplanted subcutaneously in the recipient animal. In
case of B16 melanoma 2 · 106 tumor cells were injected
intramuscularly for a mouse.
B. Tumor volume measurement
The first measurement after tumor implantation occured
when the tumors have reached an average volume of 50 −
60 mm3 [21]. It was the 5th day for C38 colon adenocarci-
noma, and the 10th day for B16 melanoma. Tumor diameters
(width, length) were measured with a digital caliper, the third
dimension of the tumor was approximated with the arithmetic
mean of its width and length, multiplied by 2/3. Thus, the
tumor volume in mm3 was calculated by the formula:
V olume = width · length ·
width+ length
2
(1)
C. Sacrificing mice
Mice were sacrificed when the tumor reached a lethal size. It
was the 24th day for C38 colon adenocarcinoma, and the 19th
day for B16 melanoma. After sacrificing the mice, the tumors
were removed, and their volume and mass was measured.
Then, tumors were cut into two pieces: one piece was stored in
formalin, and the other piece was freezed using liquid nitrogen
(with temperature of −200◦C).
Fig. 1. Investigation of C38 colon adenocarcinoma’s vascularization:
CD31 antibody (green, fluorescent) immunohistochemistry staining on frozen
sections
D. Tumor sample processing
Tumor morphology can be investigated using standard
Haematoxylin Eosin (H&E) staining [22] with the samples
stored in formalin. The freezed samples were used to create
frozen sections [23] of the tumor. Tumor vasculation can be
stained in vitro using CD31 antibody immunohistochemistry
staining [24] on frozen sections. After staining, fluorescence
pictures were done with confocal microscope (Fig. 1). From
these pictures vascularization area was calculated by ImageJ
[25] software.
IV. ANALYSIS OF EXPERIMENTAL RESULTS
In this section we analyze the measurement data acquried
from the animal experiments, and carry out parametric identi-
fication for the tumor growth dynamics supposing that tumor
growth is described by a second order linear system.
A. Experimental data
At the beginning of the experiment 12 mice were implanted
with C38 colon adenocarcinoma. One of them died in the 18th
day, and another one in the 23th day. Thus 10 mice were
sacrificed at the 24th day of the experiment.
B16 melanoma was implanted into 11 mice. One mouse
died at the 18th day, therefore 10 mice were sacrificed at the
19th day of the experiment.
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Fig. 2. Exponential curve fitting for average in case of C38 colon
adenocarcinoma (y(t) = −0.076 · exp(0.4239t) + 16.87 · exp(0.2329t)
B. Results of C38 colon adenocarcinoma experiment
Based on the tumor volume measurements, our goal is
to identify the model of tumor growth dynamics. From our
results the general assumption that tumor cells grow expo-
nentially [26] is verifiable. The simplest dynamic model is
a linear one, thus the response of the system consists of
expontential functions. Since our aim is to develop a model
for antiangiogenic therapy, we want to identify the dynamics
behind tumor growth and vasculature growth, thus we are
seeking for a second order system. The second order system
has two exponential functions in its response, thus parametric
identification was carried out by fitting a curve with two
exponential functions. The result of curve fitting on the average
of the measurents is in Fig. 2. The response of the system is
described by:
y(t) = −0.076 · exp(0.4239t) + 16.87 · exp(0.2329t) (2)
The time constants of the identified model are T1 = 2.3589
days, and T2 = 4.2938 days. The coefficients of the exponen-
tials are positive, thus the system is unstable, as it is required
from a tumor growth.
This fitting were done with Matlab and results were verified
with SPSS [27]. Using SPSS, we have examined other fitting
curve types and four curves had equal or better coefficient
of determination than 0.99 (exponential R2 = 0.990, growth
R2 = 0.990, compound R2 = 0.990, cubic R2 = 0.991).
Cubic curve fits better for the sample points than the other,
but outside of the sample range, the extrapolation is worse.
Exponential, growth and compound models fitted the same
curves.
Another model used to describe tumor growth is Gompertz
curve [28], which described a dynamic process that has a
plateu. In this model tumor cell number also depends on the
initial tumor size, the elapsed time and a constant, but at the
end of the growth period growth narrows and cell number has
a plateau:
N(t) = N0 · exp
[
ln
(
N∞
N0
[1− exp (−bt)]
)]
, (3)
where N∞ is the plateau and parameter b is related to the ini-
tial tumor growth rate. This model describes that tumor growth
is nutrient-, and oxygen-limited. However, in the plateau phase
tumor size and toxicity is lethal for the host organism without
therapy. In our experiments the last measured tumor volume is
approximately equal to the plateau cell number. Nevertheless
Gompertz curve is more difficult than the exponential one, and
may even vary considerably for patients with the same type
of cancer.
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Fig. 3. Linear regression between tumor mass and volume in case of C38
colon adenocarcinoma (R2 = 0.871, R = 0.933, p < 0.0001)
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Fig. 4. Linear regression between tumor mass and vascularization in case
of C38 colon adenocarcinoma (R2 = 0.039, R = 0.198, p = 0.584)
As discussed previously, we have measured three data of
the lethal sized tumor: tumor volume, tumor mass and vascu-
larization. We have investigated the relationship between these
tumor attributes with linear regression analysis [29]. In Fig. 3
the relationship between tumor mass and volume can be seen.
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Fig. 5. Linear regression between tumor volume and vascularization in case
of C38 colon adenocarcinoma (R2 = 0.069, R = 0.263, p = 0.462)
The coefficient of determination is R2 = 0.871, this means
that 87.1% variability in a data can be explained by the given
statistical model. Pearson correlation coefficient is R = 0.933,
thus there is a strong correlation (linear dependence) between
these variables. Using Analysis of Variance (ANOVA) test [30]
we can decide that the regression analysis is valid or not. In
this case a strong significant regression relationship can be
detected (p < 0.0001). C38 colon adenocarcinoma is a solid
tumor – this type of tumor usually does not contain cysts or
liquid area, thus tumor mass has high density.
The association between tumor mass and vascularization is
shown in Fig. 4. The coefficient of determination is R2 =
0.039, Pearson correlation coefficient is R = 0.198, and
ANOVA p-value is p = 0.584. From each parameter we can
see that there is a weak, not significant relationship between tu-
mor mass and vascularization. We get similar results in case of
tumor volume and vascularization (Fig. 5). The coefficient of
determination is R2 = 0.069, Pearson correlation coefficient
is R = 0.263, and ANOVA p-value is p = 0.462. This can be
explained by the following. Rapidly dividing tumor cells need
lots of oxygen. When proliferation begins, small sized tumor
can pick up oxygen from near capillaries. After a certain size
(1−2 mm diameter) tumor development stops, because a part
of the tumor gets too far from capillaries and can’t pick up
enough oxygen. Tumor needs own blood vessels to grow, the
process of forming new blood vessels is called angiogenesis
[31], [32]. However, due to this hurried vessel forming, a
part of tumor still can’t get enough oxygen, whereupon these
cells first inflict hypoxial reaction, then die. In C38 colon
adenocarcinoma there are several necrotic regions, thus the
whole mass cointains relatively few viable cells and vessels
[33].
C. Results of B16 melanoma experiment
In case of B16 melanoma, we were also seeking for a
linear second order system to describe the tumor growth
dynamics. The average values of the measurements and the
fitted multiexponential curve is in Fig. 6. The result of the
parametric identification is the following function:
y(t) = −511.6 · exp(0.54781t) + 512.3 · exp(0.54775t) (4)
The time constants of the system are T1 = 1.8256 days
and T2 = 1.8254 days. The parametric idenfitication results in
almost identical time constants, however the multiexponential
characteristics is important. This simple model even results in
a platue like characteristics at high tumor volume values (Fig.
6.), without the nonlinear model of the Gompertzian growth.
The coefficients of the exponential functions are positive in
this case as well, resulting in an unstable system.
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Fig. 6. Exponential curve fitting for average in case of B16 melanoma
(y(t) = −511.6 · exp(0.54781t) + 512.3 · exp(0.54775t)
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Fig. 7. Linear regression between tumor mass and volume in case of B16
melanoma (R2 = 0.421, R = 0.649, p = 0.042)
As at analysis of C38 colon adenocarcinoma, this fitting
was also done with Matlab and results were verified with
SPSS. Examined best fitting curve types and coefficient of
determination values are: exponential R2 = 0.955, growth
R2 = 0.955, compound R2 = 0.955, cubic R2 = 0.981.
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Also in this case cubic fits better, but has the same problem
(wrong extrapolation and prediction). Exponential, growth and
compound models fitted the same curves.
In Fig. 7 the relationship between tumor mass and volume
can be seen. The coefficient of determination is R2 = 0.421,
Pearson correlation coefficient is R = 0.649. These param-
eters show correlation, but not as strong as in case of C38
colon adenocarcinoma. Using ANOVA test, also a weaker, but
significant regression relationship can be detected (p = 0.042).
B16 melanoma is a solid tumor as well, but cell growth leads
to necrosis and liquefaction of muscle tissues. Because of that
the removed mass contains liquefied areas, which have lower
density.
The association between tumor mass and vascularization is
shown in Fig. 8. The coefficient of determination is R2 =
0.215, Pearson correlation coefficient is R = 0.463, and
ANOVA p-value is p = 0.177. The relationship between tumor
volume and vascularization can be seen in Fig. 9. The coef-
ficient of determination is R2 = 0.029, Pearson correlation
coefficient is R = 0.170, and ANOVA p-value is p = 0.638.
Vascularization does not have significant relationship with
tumor mass, neither with tumor volume.
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Fig. 8. Linear regression between tumor mass and vascularization in case
of B16 melanoma (R2 = 0.215, R = 0.463, p = 0.177)
V. CONCLUSION
Our results show that tumor growth dynamics can be
described with a second order linear system. Examining the
tumor attributes, we can say that not each attributes correlates,
thus not only tumor mass and tumor volume is important
to measure. The relevant tumor attribute, that have to be
measured is based on the therapy applied. In case of an-
tiangiogenic therapy, vascularization can be more important
than tumor mass or tumor volume. Further work will be
contain other mouse experiments, where we will investigate
tumor growth under antiangiogenic therapy. Moreover, other
modelling aspects will be investigated similar to [34], [35],
[36].
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Fig. 9. Linear regression between tumor volume and vascularization in case
of B16 melanoma (R2 = 0.029, R = 0.170, p = 0.638)
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